Oeiras, Portugal – 4 January 2010.

Biotecnol will be present at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco on January 11th to 14th , 2010. This event is the premier conference of its kind, bringing together established industry leaders, emerging fast-growth companies, innovative technology creators and globally minded service providers. This year we expect more than 300 companies, both public and private, to deliver presentations to more than 3,500 investors.

Biotecnol´s CEO Dr. Pedro de Noronha Pissarra will be available to discuss the company´s progress in the development of multifunctional antibody molecules, directed to key therapeutic targets. Based on its Tribody™ technology, Biotecnol is developing a pipeline of products for application in major disease areas such as oncology. He can be contacted by email at pnp@biotecnol.com or via the Connecting SF  Portal www.connectingsf.com